ADA Scientific Sessions 2026: key results and trends

Mean HbA1c decreased by 1.54 to 2.05% in the OFG groups vs 0.77% with PBO.

At week 24, HbA1c decreased 0.83% in anagliptin group versus 0.03% in placebo (difference -0.80%; 95% CI -0.95 to -0.64; P<0.0001).

At Week 24, HTD1801 produced an HbA1c reduction of -1.12% vs -0.93% for Dapa with a LS mean difference of -0.20% (95% CI, -0.37%, -0.03%; p<0.001), confirming non-inferiority.

In Period 1, HbA1c was reduced by 0.45% (95% CI -0.78, -0.127; p=0.0072) and body weight was reduced by 10.2 kg (95% CI -12.8, - 7.7; p<0.0001) by semaglutide vs SOC.

After 4.6 y median f/u, evo decreased 3-P MACE by 29% vs pbo in pts w/ HR-DM and 21% in those w/o HR-DM (Pint 0.47).

The most common adverse events were gastrointestinal (GIAEs), including nausea (30.5% with mazdutide; 12.6% with semaglutide), diarrhoea (27.0%; 21.8%), and vomiting (23.6%; 8.6%), and mostly mild to moderate in severity.

Non inferiority was confirmed for the primary endpoint for BCLIS: A1C was reduced by 0.65% (BCLIS) and 0.57% (LIS): estimated treatment difference of -0.07% [95% CI -0.18; 0.03].

From a mean baseline A1C of ~7.7%, SOTA 200 mg and 400 mg significantly reduced A1C versus PBO by 0.4%.

The proportion of participants with hyperfiltration decreased in pooled TZP (18.6% to 5.5%) and increased in PBO (16.1% to 21.9%, p<0.05, TZP vs PBO).

Compared with placebo, the 50 mg & 80 mg doses of olezarsen reduced TGs by 57.4% (95% CI 48.6-66.2) and 64.8% (56.0-73.6) in pts with DM, respectively, and by 57.0% (45.7-68.3) and 65.1% (53.9-76.4) in pts w/o DM.

HDM1005 also improved cardiometabolic parameters from baseline (difference relevant to placebo) in waist circumference (up to -7.27 cm), SBP (up to -10.19 mmHg), DBP (up to -6.13 mmHg), TG (up to -36.99%), LDL-C (up to -8.19%) and non-HDL-C (up to -11.88%).

Least-squares (LS) mean changes in HbA1c for HDM1002 50, 100, 200, 400 mg QD and 200mg BID were -1.06%, -0.82%, -0.94%, -1.29% and -1.23%, respectively.